BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1205 related articles for article (PubMed ID: 33396184)

  • 1. The Two-Way Switch Role of ACE2 in the Treatment of Novel Coronavirus Pneumonia and Underlying Comorbidities.
    Pang XC; Zhang HX; Zhang Z; Rinkiko S; Cui YM; Zhu YZ
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33396184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
    Shukla AK; Banerjee M
    High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides.
    Freitas FC; Ferreira PHB; Favaro DC; Oliveira RJ
    J Chem Inf Model; 2021 Mar; 61(3):1226-1243. PubMed ID: 33619962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
    Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
    Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico investigation of critical binding pattern in SARS-CoV-2 spike protein with angiotensin-converting enzyme 2.
    Jafary F; Jafari S; Ganjalikhany MR
    Sci Rep; 2021 Mar; 11(1):6927. PubMed ID: 33767306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.
    Shin YH; Jeong K; Lee J; Lee HJ; Yim J; Kim J; Kim S; Park SB
    Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202115695. PubMed ID: 35043545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of SARS-CoV-2 on Cardiovascular System: The Dual Role of Angiotensin-Converting Enzyme 2 (ACE2) as the Virus Receptor and Homeostasis Regulator-Review.
    Aleksova A; Gagno G; Sinagra G; Beltrami AP; Janjusevic M; Ippolito G; Zumla A; Fluca AL; Ferro F
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33926110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
    Xiang Y; Wang M; Chen H; Chen L
    Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of Angiotensin-Converting Enzyme 2: A Potential Target to Prevent COVID-19?
    Hu Y; Liu L; Lu X
    Front Endocrinol (Lausanne); 2021; 12():725967. PubMed ID: 34745001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
    Kuba K; Yamaguchi T; Penninger JM
    Front Immunol; 2021; 12():732690. PubMed ID: 35003058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repositioning of histamine H
    Ge S; Wang X; Hou Y; Lv Y; Wang C; He H
    Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can Host Cell Proteins Like ACE2, ADAM17, TMPRSS2, Androgen Receptor be the Efficient Targets in SARS-CoV-2 Infection?
    Gupta VK; Murthy MK; Patil S
    Curr Drug Targets; 2021; 22(10):1149-1157. PubMed ID: 33243116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: A pathway-based analytical study.
    Parit R; Jayavel S
    Eur J Pharmacol; 2021 Apr; 896():173899. PubMed ID: 33508281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
    Nayak SK
    Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrinsic disorder perspective of an interplay between the renin-angiotensin-aldosterone system and SARS-CoV-2.
    Elrashdy F; Redwan EM; Uversky VN
    Infect Genet Evol; 2020 Nov; 85():104510. PubMed ID: 32853823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery.
    Lores E; Wysocki J; Batlle D
    Clin Sci (Lond); 2020 Nov; 134(21):2791-2805. PubMed ID: 33135725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CL
    Mouffouk C; Mouffouk S; Mouffouk S; Hambaba L; Haba H
    Eur J Pharmacol; 2021 Jan; 891():173759. PubMed ID: 33249077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Manipulation of ACE2 expression in COVID-19.
    Chaudhry F; Lavandero S; Xie X; Sabharwal B; Zheng YY; Correa A; Narula J; Levy P
    Open Heart; 2020 Dec; 7(2):. PubMed ID: 33443121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.